Claudin 6: A Novel Target for Solid Tumors

In the ongoing search for new cancer treatments, companies including Context Therapeutics are developing potential therapies focused on the emerging novel oncology target Claudin 6 (CLDN6). CLDN6 is a membrane bound protein that is expressed in multiple solid tumors, including ovarian, lung, and testicular, and absent from or expressed at low levels in healthy adult tissues. Emerging T cell engager assets highlight CLDN6-targeted therapeutic modalities that could enhance the treatment of CLDN6-positive tumors.